Literature DB >> 12053125

Increased blood-brain barrier permeability in white matter lesions of Binswanger's disease evaluated by contrast-enhanced MRI.

Haruo Hanyu1, Tetsuichi Asano, Yuriko Tanaka, Toshihiko Iwamoto, Masaru Takasaki, Kimihiko Abe.   

Abstract

We investigated blood-brain barrier (BBB) permeability in white matter lesions of Binswanger's disease (BD) with contrast-enhanced MRI. Three subject groups were studied: 17 patients with BD and periventricular hyperintensities (PVH) on MRI, 10 patients with ischemic cerebrovascular events and with PVH but no dementia, and 14 age-matched control subjects without PVH. BBB permeability was quantified by calculation of T(1) change defined as [(T(1post) - T(1pre))/T(1pre)] x100, where T(1pre) and T(1post) represent the T(1) relaxation times before and after Gd-DTPA administration. T(1) change in PVH of BD patients significantly decreased in comparison with that observed in PVH of the nondemented patients and in normal white matter of the control subjects, but no significant T(1) change was observed between the PVH of the nondemented patients and normal white matter of the controls. There was a significant correlation between the Mini-Mental State Examination score and T(1) change for areas of PVH in BD. These results suggest that BBB permeability increases in areas of PVH in BD and that a BBB dysfunction is related to a progression of cognitive impairment. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12053125     DOI: 10.1159/000058326

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  28 in total

Review 1.  Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?

Authors:  Santiago Rivera; Michel Khrestchatisky; Leszek Kaczmarek; Gary A Rosenberg; Diane M Jaworski
Journal:  J Neurosci       Date:  2010-11-17       Impact factor: 6.167

2.  Blood-brain barrier and Alzheimer's.

Authors:  Jim Sondecker; Michael Smith; Dave Robinson
Journal:  Psychiatry (Edgmont)       Date:  2005-06

Review 3.  The blood-brain barrier: geriatric relevance of a critical brain-body interface.

Authors:  Neer Zeevi; Joel Pachter; Louise D McCullough; Leslie Wolfson; George A Kuchel
Journal:  J Am Geriatr Soc       Date:  2010-09       Impact factor: 5.562

4.  Alzheimer's disease and the Blood-Brain Barrier: Past, Present and Future.

Authors:  Gene L Bowman; Joseph F Quinn
Journal:  Aging health       Date:  2008-02-01

5.  Quantitative measurement of blood-brain barrier permeability in human using dynamic contrast-enhanced MRI with fast T1 mapping.

Authors:  Saeid Taheri; Charles Gasparovic; Nadim Jon Shah; Gary A Rosenberg
Journal:  Magn Reson Med       Date:  2010-12-13       Impact factor: 4.668

6.  Blood-brain barrier permeability abnormalities in vascular cognitive impairment.

Authors:  Saeid Taheri; Charles Gasparovic; Branko N Huisa; John C Adair; Elaine Edmonds; Jillian Prestopnik; Mark Grossetete; N Jon Shah; John Wills; Clifford Qualls; Gary A Rosenberg
Journal:  Stroke       Date:  2011-06-30       Impact factor: 7.914

Review 7.  Binswanger's disease: toward a diagnosis agreement and therapeutic approach.

Authors:  Branko N Huisa; Gary A Rosenberg
Journal:  Expert Rev Neurother       Date:  2014-09-09       Impact factor: 4.618

8.  Matrix metalloproteinases are associated with increased blood-brain barrier opening in vascular cognitive impairment.

Authors:  Eduardo Candelario-Jalil; Jeffrey Thompson; Saeid Taheri; Mark Grossetete; John C Adair; Elaine Edmonds; Jillian Prestopnik; John Wills; Gary A Rosenberg
Journal:  Stroke       Date:  2011-03-31       Impact factor: 7.914

9.  Cobalamin deficiency, hyperhomocysteinemia, and dementia.

Authors:  Steven F Werder
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

Review 10.  Matrix Metalloproteinase-Mediated Neuroinflammation in Vascular Cognitive Impairment of the Binswanger Type.

Authors:  Gary A Rosenberg
Journal:  Cell Mol Neurobiol       Date:  2016-03-18       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.